Braveheart Bio is a late clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy and related conditions. The company is backed by experienced life science investors and is advancing BHB-1893 through late-stage clinical development with the goal of establishing a new standard of care.
